Unresectable, metastatic or locally advanced ALK-positive NSCLC.
Must have received lorlatinib as first or second line TKI
One prior line of systemic chemotherapy is permitted
Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose
You may not be if
Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression
Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)
Clareo Health | Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
